GlassScriptPhysician profile
Saurabh Agrawal
NPI 1194990499
$36,192.07
in general payments reported to CMS, 2019-2025
14 companies · $31K in 2025
The $31K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $1,860 · 2021: $121 · 2022: $2,491 · 2023: $229 · 2024: $125 · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Travel and Lodging: $1,823 · Consulting Fee: $1,820 · Food and Beverage: $1,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,852.00 |
| Travel and Lodging | $1,823.44 |
| Consulting Fee | $1,820.00 |
| Food and Beverage | $1,113.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $29,412.99 | 2024-2025 | Iqirvo, Bylvay |
| Astrazeneca Pharmaceuticals LP | $4,332.59 | 2020-2022 | |
| Novo Nordisk INC | $1,869.46 | 2025 | Wegovy |
| Boston Scientific Corporation | $148.95 | 2023 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Cook Medical LLC | $121.25 | 2021 | |
| Exelixis INC. | $111.29 | 2019 | |
| Abbott Laboratories | $80.43 | 2023 | Cardiomems |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.99 | 2025 | Xifaxan |
| Orphalan INC | $24.85 | 2025 | Cuvrior |
| Takeda Pharmaceuticals U.S.A., INC. | $24.33 | 2025 | Entyvio |
| Alnylam Pharmaceuticals INC. | $17.94 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saurabh Agrawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.